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Sarcoidosis is an enigmatic disorder with a propensity for lung involvement in 
the majority of cases (~90%) and is characterized by noncaseating granulomatous 
inflammation on histological analysis. The techniques to establish the diagnosis have 
evolved over time, and a clear diagnostic algorithm for the clinicians dealing with 
this disease is desirable. Thoracic computed tomography is the imaging modality 
of choice in pulmonary sarcoidosis and provides accurate assessment of staging, 
parenchymal involvement, and response to immunomodulatory therapies. The 
advent of EBUS-TBNA has been a step forward with an excellent diagnostic yield in 
the presence of mediastinal/hilar lymphadenopathy and has replaced the traditional 
approach of obtaining biopsy samples via transbronchial and endobronchial routes. 
The preferred initial investigation for the confirmation of diagnosis is dependent on 
the organ involvement and the expertise available. A core biopsy of cervical lymph 
nodes is a less invasive and economical alternative in selected cases of suspected 
pulmonary sarcoidosis and warrants further evaluation in prospective manner to 
establish if it can be considered as a first-line investigation in all new cases suspected 
to have pulmonary sarcoidosis. A multidisciplinary approach is crucial for the 
diagnosis and management, and a simplified algorithm is proposed to help guide cli-
nicians dealing with this disease of myriad clinical and radiological manifestations.
Keywords: sarcoidosis, granulomatous inflammation, lymphadenopathy, core 
biopsy, endobronchial ultrasound-guided transbronchial needle aspiration 
(EBUS-TBNA)
1. Introduction
Sarcoidosis is an enigmatic disorder with a propensity for lung involvement in 
the majority of cases (90%) and is characterized by noncaseating granulomatous 
inflammation on histological analysis. The techniques to establish the diagnosis 
have evolved over time, and a clear diagnostic algorithm for clinicians dealing with 
this disease is desirable. Thoracic computed tomography is the imaging modality 
of choice in pulmonary sarcoidosis and provides accurate assessment of the stage, 
parenchymal involvement, and response to immunomodulatory therapies. The 
advent of EBUS-TBNA has been a step forward with an excellent diagnostic yield 
in the presence of mediastinal/hilar lymphadenopathy and has replaced the tradi-
tional approach of obtaining biopsy samples via transbronchial and endobronchial 
routes. The preferred initial investigation for the confirmation of diagnosis is 
dependent upon the organ involved and the expertise available. A core biopsy of 
cervical lymph nodes is a less invasive and economical alternative in selected cases 
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of suspected pulmonary sarcoidosis and warrants further evaluation in a prospec-
tive manner to establish if it can be considered a first-line investigation in all new 
cases suspected to have pulmonary sarcoidosis. A multidisciplinary approach is 
crucial for the diagnosis and management; a simplified algorithm is proposed to 
help guide clinicians dealing with this disease of myriad clinical and radiological 
manifestations.
Sarcoidosis is a disease of uncertain etiology characterized by evidence of non-
necrotizing granulomatous inflammation on histological assessment. As the disease 
commonly affects the lungs, the patients are likely to be referred to pulmonolo-
gists for further investigations. Chest radiography is usually the first investigation 
carried out in the primary care setting suggesting the possibility of hilar lymph 
node enlargement, and sarcoidosis has traditionally been staged according to chest 
radiographic appearances (Figure 1).
Radiological assessment of sarcoidosis has been revolutionized by high-
resolution computed tomography (HRCT) scanning of lungs and is currently the 
best available modality to assess the extent of involvement of lung parenchyma/
interstitial compartment and response to immunomodulatory therapies to evaluate 
alveolitis and reversibility of the disease process. The current diagnostic techniques 
for histological assessment in pulmonary sarcoidosis are invasive, and there is a 
need for a less invasive approach to obtain tissue sample(s). This chapter aims to 
discuss the available diagnostic techniques in sarcoidosis and propose an algorithm 
to the pulmonologists/radiologists and clinicians dealing with sarcoidosis as a tool 
to aid for reaching the diagnosis with minimally invasive investigations. It is recom-
mended that an ultrasound-guided core biopsy of cervical lymph nodes (along 
with assessment of parotid glands) may be considered first-line investigation in the 
presence of mediastinal and or hilar lymphadenopathy, a suitable target to sample 
neck lymph nodes.
2. Diagnostic techniques
The diagnosis of sarcoidosis is best supported by the presence of noncaseating/
necrotizing granulomatous inflammation on histological analysis, following the 
exclusion of other granulomatous disorders such as mycobacterial or fungal diseases 
on special immunohistochemical stains. The diagnostic techniques for sarcoidosis 
can be subclassified into four groups:
Figure 1. 
Chest radiograph appearances according to stage of sarcoidosis.




• Ultrasound-guided biopsy techniques
• Surgical techniques
2.1 Radiological imaging techniques
These include chest radiography, high-resolution computed tomography, and 
positron emission tomography (PET) scanning.
2.1.1 Chest radiography
The typical chest radiographic appearances in sarcoidosis consist of symmetric 
bilateral hilar and mediastinal lymphadenopathy. Fibrosis is noticed in 5–25% of 
patients with sarcoidosis on initial chest radiograph [1]. Figure 2 demonstrates 
an example of advanced stage sarcoidosis with the development of fibrosis and 
parenchymal distortion.
2.1.2 High-resolution computed tomography
High-resolution computed tomography has improved the diagnostic accuracy 
of sarcoidosis in terms of parenchymal involvement (Figure 3) and assessed any 
reversible component such as alveolitis that may not be readily evident on chest 
radiography. Moreover, the abnormalities on HRCT scan do correlate better with 
respiratory functional impairment than chest radiograph findings [2].
Sarcoidosis is a disease with a myriad of radiological abnormalities on HRCT, 
including hilar and mediastinal lymphadenopathy, ground glass abnormality, and 
fibrosis in a peribronchovascular, perilymphatic distribution, pulmonary paren-
chymal nodules, and beading of the fissures. There is a mid- to upper-zone prepon-
derance of these abnormalities and usually distributed along the bronchovascular 
Figure 2. 
Stage III sarcoidosis with evidence of hilar lymphadenopathy and parenchymal involvement.
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bundles [3]. HRCT may be able to demonstrate lymphadenopathy in mediastinal 
distribution better than a chest radiograph and sometimes demonstrate evidence of 
calcification within these nodes (Figure 4).
The precise role of HRCT in the clinical monitoring of sarcoidosis is unknown. 
However, it may prove to be a useful tool to assess acute alveolitis and inflammation 
in selected cases of refractory sarcoidosis, where treatment decisions to commence 
Figure 3. 
Parenchymal distortion with fibrosis in a peribronchovascular distribution in bilateral upper lobes in 
sarcoidosis.
Figure 4. 
Calcified mediastinal lymphadenopathy with bilateral hilar nodal enlargement in a patient with confirmed 
sarcoidosis.
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biologic therapies such as infliximab are being made [3]. A study by De Boer et al. 
showed that the total extent of parenchymal disease on the CT scan on a lobar 
basis could predict the likelihood of transbronchial biopsy being positive following 
bronchoscopy [4], demonstrating its utility on diagnostic grounds.
2.1.3 Positron emission tomography scan
Positron emission tomography scan can be a useful tool to detect the extent of 
the disease, identify multisystem disease such as cardiac sarcoidosis, and may help 
to identify a desirable site for biopsy [5]. Moreover, it could be invaluable in the 
decision to initiate immunosuppression and assess the efficacy of treatment [6, 7]. 
Furthermore, it may help in predicting relapse in pulmonary sarcoidosis [8].
A retrospective study by Teirstein et al. showed that a combination of diag-
nostic modalities such as 18F-fluorodeoxyglucose (FDG-PET) and CT scan is 
more sensitive than PET-only imaging [9]. Whole-body FDG-PET was found to be 
significantly better in identifying occult and reversible granulomas. Moreover, a 
positive PET scan in isolation should not be considered as an indication for treat-
ment. In another study by Yu et al., the sensitivity and specificity for benign and 
malignant disease were 94.2% and 73.8%, respectively [10]. It was, however, noted 
that maximum standard uptake value (SUVMax) as semiquantitative measurement 
alone could not be used to differentiate benign vs. malignant lesions.
The FDG-PET scan has a cumulative effect in cardiac sarcoidosis. PET scan 
has also been evaluated in predicting supraventricular arrhythmias, and it was 
noted that patients with left atrial enlargement were associated with increased 
likelihood of supraventricular arrhythmias [11]. Smedema et al. reported that 
biventricular late gadolinium enhancement was the strongest predictor of adverse 
outcome, and an asymptomatic myocardial scar of less than 8% in the left ven-
tricular mass was associated with a favorable outcome in patients with pulmonary 
sarcoidosis [12].
On the basis of current available evidence, the role of PET-CT is limited in 
routine clinical care of patients with pulmonary sarcoidosis. However, it may be a 
useful imaging modality in multisystem sarcoidosis, in particular when the clinical 
suspicion for cardiac involvement is high and the diagnostic techniques such as 
echocardiography and or cardiac MRI have unequivocal results. Moreover, PET-CT 
may become a useful adjunct to assess the response to immunosuppression with 
corticosteroids and/or antimetabolites and may guide us to an appropriate biopsy 
site to sample suspected multisystem disease.
2.2 Bronchoscopic techniques
2.2.1 Bronchoalveolar lavage (BAL) and transbronchial biopsy (TBB)
Bronchoscopic techniques have been employed in the evaluation of pulmonary 
sarcoidosis for a very long time and have been the mainstay of histological confir-
mation historically. Granulomatous inflammation in sarcoidosis usually involves the 
bronchovascular and centrilobular structures.
Transbronchial biopsies help to obtain the histological diagnosis in support of 
clinical-radiological diagnosis especially when the superficial mucosal or cutaneous 
lesions are not amenable for sampling [13, 14]. The diagnostic sensitivity of TBB 
in the diagnosis of a broad spectrum of interstitial lung diseases (ILDs) ranges 
from 29 to 79% [15–19]. The British Thoracic Society Sarcoidosis Registry data has 
previously showed that transbronchial biopsies have lesser diagnostic yield than 
EBUS-TBNA [20].
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Bronchoalveolar lavage findings supportive of sarcoidosis include predominant 
lymphocytosis on differential cell count analysis along with CD4/CD8 lymphocyte 
ratio of more than 1. Müller-Quernheim et al. demonstrated that inflammation 
is compartmentalized in sarcoidosis resulting in lymphocyte abundance in the 
involved organs [21]. In a study by Prasse et al., patients with sarcoidosis had higher 
expression of IL2, IFN gamma, and TNF alpha [22]. Furthermore, Tanriverdi et al. 
showed that high CD4/CD8 ratio, though specific is not a sensitive test for the diag-
nosis of sarcoidosis, and therefore, it does require clinico-radiological and pathologi-
cal correlation [23]. BAL lymphocytosis of ≥40% in the appropriate clinical context 
would support the diagnosis of hypersensitivity pneumonitis or cellular nonspecific 
interstitial pneumonia (NSIP) over sarcoidosis [24]. However, bronchoalveolar 
lavage findings in isolation are unlikely to help establish the diagnosis of sarcoidosis.
2.2.2  Endobronchial ultrasound-guided transbronchial needle aspiration 
(EBUS-TBNA)
EBUS-TBNA has been significant in the diagnostic pathway of sarcoidosis and 
has obviated the need for a TBB (in most cases where mediastinal adenopathy is 
present) with associated risk of pneumothorax. EBUS-TBNA is a safe minimally 
invasive option and is the preferred diagnostic procedure before surgical techniques 
such as mediastinoscopy are considered for sampling mediastinal nodes [25].
Kitamura et al. demonstrated a sensitivity of 87.5% for combined cytological 
and histological examination [26]. A prospective study by Oki et al. compared 
the diagnostic yield of EBUS-TBNA and TBLB through a flexible bronchoscope in 
patients with stage I and II of sarcoidosis [27]. The diagnostic yield was 94% (stage 
I, 97%; stage II, 88%) and 37% (stage I, 31%; stage II, 50%), respectively; the 
complications such as pneumothorax and moderate bleeding were noted in patients, 
who underwent TBLB, albeit one case of pneumothorax and three cases of moder-
ate bleeding among a total of 62 patients were seen.
A randomized controlled trial evaluated the use of endosonographic nodal 
aspiration against bronchoscopic biopsy, among patients with suspected stage 
I/II pulmonary sarcoidosis [28]. The diagnostic yield to detect granulomas for 
endosonography was 80% (95% CI, 73–86%), in comparison to 53% (95% CI, 
45–61%) for bronchoscopy cohort (P < 0.001), suggesting a significantly higher 
diagnostic yield with endosonographic procedures. On the other hand, a random-
ized controlled trial by Gupta et al. showed that the diagnostic yield in sarcoidosis 
by conventional TBNA along with endobronchial biopsy (EBB) and TBLB is similar 
to EBUS-TBNA with TBLB [29].
The diagnostic accuracy of EBUS-TBNA with rapid on-site evaluation (ROSE) was 
compared to the final cytological assessment and to TBLB and EBB in a prospective 
study, and it showed that sensitivity for EBUS-TBNA with ROSE was 87.8% (specific-
ity 91%, positive predictive value 97.7%) and concluded that it should be considered 
as first-line investigation for the evaluation of mediastinal adenopathy [30].
In patients with predominant mediastinal and/or intra-abdominal lymph nodes, 
which is not amenable for EBUS procedure, endoscopic ultrasound-guided fine 
aspiration (EUS-FNA) can be a potential option; Michael et al. demonstrated in a 
retrospective study that [31] EUS-FNA was able to diagnose sarcoidosis in 86% of 
cases (n = 18 of 21) and was able to rule out recurrence of malignancy in 75% (three 
out of four cases).
2.2.3 Transbronchial lung cryobiopsy (TBLC)
Transbronchial lung cryobiopsy is currently being increasingly considered as a 
diagnostic tool in ILD. The procedure requires general anesthesia and fluoroscopic 
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guidance for sampling with a cryoprobe [32]. In a retrospective study by Jacob et al., 
they were able to demonstrate a diagnostic yield of up to 92.6% on a small sample 
size in the study [33]. The main advantage of TBLC is related to larger biopsy 
sample in comparison to traditional transbronchial biopsy with associated crushing 
artifact of the sample. However, TBLC has the limitations related to training and the 
need for general anesthesia. Moreover, there is a significant risk of complications 
including pneumothorax and bleeding ranging from 9 to 10% and from 14 to 20%, 
respectively [34].
Hagmeyer et al. demonstrated that the risk of severe complications can be 
reduced from 84 to 14% by technical modification of this procedure. Hence, it may 
prove to be a useful step before consideration of surgical lung biopsy [35].
2.3 Ultrasound (US)-guided biopsy
The diagnostic workup for sarcoidosis should include the least invasive inves-
tigation at the outset of evaluation; thus, neck ultrasound may provide an ideal 
modality for that purpose. We have demonstrated that a core biopsy of cervi-
cal lymph nodes (ranging from 7 to 14 mm in diameter), with no sonographic 
appearance of being marked was adequate to make a histological diagnosis of 
sarcoidosis [36]. In this retrospective analysis, we showed that if there were no 
suitable cervical lymph node for biopsy, an US evaluation and biopsy of abnor-
mal parotid glands may help establish the diagnosis of sarcoidosis [36]. In view 
of the ease of this procedure and its cost-effectiveness (approximately £1000/= 
saving in comparison to EBUS-TBNA per patient in the UK), this could poten-
tially be considered as a first-line investigation if appropriate expertise is avail-
able. Hence, it is proposed that the diagnostic algorithm as shown in Figure 5 
for the investigation of mediastinal lymphadenopathy should include US-guided 
core biopsy of cervical lymph nodes +/− parotid glands if deemed abnormal. 
We envisage that a prospective multicenter study of wider application of this 
technique would be desirable to generalize the use of this minimally invasive 
diagnostic modality.
2.4  Surgical techniques: cervical mediastinoscopy and video-assisted 
thoracoscopy (VATS)
2.4.1 Cervical mediastinoscopy
Cervical mediastinoscopy (CM) is one of the preferred surgical techniques to 
evaluate mediastinal lymphadenopathy. The procedure helps to obtain samples 
from paratracheal and subcarinal lymph nodes. Since the advent of EBUS-TBNA, 
EUS-FNA, and PET-CT, the frequency of mediastinoscopy as a diagnostic pro-
cedure has declined significantly. Moreover, it is reserved when the above tech-
niques have been inconclusive or not feasible due to the location of the enlarged 
lymph node.
Onat et al. reported the safety of CM and demonstrated that it is a reliable 
method, in the evaluation of mediastinal lymphadenopathy [37]. In a meta-analysis 
by Agarwal et al., they reported a diagnostic yield between 82 and 97% for cervical 
mediastinoscopy [38].
2.4.2 Video-assisted thoracoscopic surgery (VATS)
VATS biopsy should be considered when there is difficulty in establishing the 
diagnosis with other less invasive options especially if a specific histological diag-
nosis would help the prognosis or treatment [39]. The diagnostic yield, sensitivity, 
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and specificity of VATS reported in a meta-analysis were 92.7% (87.6–95.8%), 91% 
(89–92%), and 58% (31–81%), respectively [40]. VATS procedures have the advan-
tage of technically enabling multilobed biopsies in comparison to open lung biopsy 
[41]. Currently, mini-VATS is also being increasingly considered given the less 
postoperative complications and decreased length of hospital stay [42, 43]. VATS 
procedure should be done by experienced thoracic surgeons, as there is a potential 
need for mini-thoracotomy in 25% of cases, to obtain adequate tissue for diagnosis 
[44]. Furthermore, there is a mortality rate of approximately 2% at 30 days associ-
ated with this surgical procedure as demonstrated by a meta-analysis conducted by 
Wallis et al. [45].
3. Conclusion
Sarcoidosis presents as a diagnostic dilemma in a number of medical specialties 
ranging from pulmonology, general internal medicine, rheumatology, and oncol-
ogy to name a few. The advent of ultrasound-guided techniques (EBUS-TBNA, 
EUS-TBNA, and US-guided core biopsy of neck nodes) has significantly reduce the 
frequency of more invasive diagnostic procedures such as mediastinoscopy and sur-
gical lung biopsies (both open and VATS biopsies). Moreover, TBB is rarely required 
to sample the lung parenchyma as the diagnostic yield of alternative procedures, 
with much less associated risk of pneumothorax (EBUS, EUS and US-guided core 
biopsy of neck nodes), is very high in appropriate clinical context. TBLC may be 
a newer diagnostic intervention being utilized in selected centers for histological 
Figure 5. 
Diagnostic approach in suspected pulmonary sarcoidosis. EBUS-TBNA, endobronchial ultrasound-guided 
transbronchial needle aspiration; TBB, transbronchial biopsy; EBB, endobronchial biopsy; VATS, video-
assisted thoracoscopic biopsy [36].
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assessment of ILDs, but its role in the diagnostic pathway is uncertain at present. 
However, future studies may shed light on its value in the diagnostic pathway of 
ILD. It is proposed that expertise for US-guided neck node core biopsy would be an 
important adjunct in the armory of interventional radiologists skill sets and has the 
potential to be a safe and cost-effective procedure in suspected pulmonary sar-
coidosis. Furthermore, learning this technique to sample near normal-sized lymph 
nodes would be appropriate in minimizing bronchoscopic procedures, preventing 
significantly higher morbidity.
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